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01 Graves’ Disease
Case History
A previously fit 32-year-old woman notices tremor and heat intolerance. She has lost one and
a half stones (9.5 kg) in weight over the past 6 months. You note signs of hyperthyroidism and
a diffuse goitre. Her mother is treated for hypothyroidism. The patient smokes 20 cigarettes
per day. She and her husband want to start a family in the foreseeable future.
How should she be investigated?
Does she require a thyroid scan?
What is the preferred first line of treatment?
If she has a child, how likely is the child to be affected by Graves’ disease?
© Atlas Medical Publishing Ltd 2007
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Background
Thyrotoxicosis occurs in 2% of women and 0.2% of men. In younger people, Graves’ dis-
ease is by far the commonest diagnosis, with peak onset at 20–40 years. Treatment is with
drugs, radioactive iodine or surgery. Thionamide drugs are generally the first line of therapy
in young women.1,2 They have been used for over 50 years. They are safe and well tolerated.
Up to 10% of patients experience mild side effects including urticaria, skin rash, joint pain,
altered taste and nausea. These do not usually necessitate stopping the drug. The most seri-
ous side effect is agranulocytosis which occurs in less than 0.4%. Patients should always be
warned to report skin rash, sore throat or any other untoward side effect, and this warning
should be recorded in their notes. If side effects are reported, full blood count and differen-
tial should be requested urgently and consideration should be given to stopping the drug.
There are three thionamide drugs—carbimazole (CBZ), methimazole (MMI), and
propylthiouracil (PTU). They are similar in their clinical effect. There have been no sub-
stantial head-to-head studies comparing them. CBZ is the most commonly used drug in
the UK, whereas MMI is used in the USA and in many European countries. PTU is usual-
ly used as second line treatment. It has a shorter duration of action and therefore is best
given in divided doses. PTU may have free radical scavenging activity, and it is not the
drug of first choice before or after radioactive iodine because it may diminish the effect-
iveness of the latter. Skin rashes may be commoner with MMI—reported rate in trials
was 7% for CBZ compared with 12% for MMI.2 PTU is the drug of choice in acute severe
thyrotoxicosis as it decreases conversion of T4 to T3.
In practice, duration of antithyroid treatment does not appear to be critical.
Endocrinologists have all encountered patients who stop taking their drugs after a few
months and do not relapse and others who relapse even after prolonged treatment. There
is consensus that patients should be treated for at least 6 months, and certainly until
serum thyrotropin (TSH) is no longer suppressed and levels of TSH receptor antibodies
(TBII) have decreased. Longer treatment may lead to decrease in goitre size, and
thus lower risk of relapse. Evidence slightly favours longer than 6 months’ treatment;
common practice is between 12 and 18 months, and there is no evidence to favour longer
treatment.
Most endocrinologists commence patients on high dose and gradually decrease to main-
tenance dose according to response. Block and replace regimens were based on the hypoth-
esis that antithyroid drugs had immune-modulating and antioxidant properties, and thus
may modify the natural history of the disease. Exposure to higher doses of the drug for
longer necessitates concurrent thyroid hormone treatment. The two regimens have been
compared in 12 studies involving a total of over 1700 patients. The compliance with follow-
up varied in these studies. On an intention-to-treat basis, and with follow-up greater than
2 years, relapse rate is just over 50% with either regimen. Higher dose of drug increases risk
of side effects. There was no difference in the incidence of agranulocytosis. However, skin
rashes were more common in block and replace studies—10% for block and replace vs. 5%
for titration (odds ratio [OR] 2.62; 95% confidence interval [CI] 1.20 to 5.75). More people
withdrew because of side effects in the block and replace groups.
Treatment with thyroxine following antithyroid drugs was hypothesized to decrease
autoantigen exposure and thus lower relapse rate. Three studies have combined thyroxine
and low-dose antithyroid drug after initial stabilization with antithyroid drug. No differ-
ence in relapse rate was found. In three further studies, antithyroid drug was followed by
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a period of thyroxine treatment. In these studies relapse rate was 31% in the thyroxine-
treated patients and 29% in those treated with placebo (not significant).
Thyrotoxicosis may temporarily worsen after 131I because of a combination of radi-
ation-induced thyroiditis and increased TBII. Severe exacerbation occurs in less than 1%.
Antithyroid drugs are frequently used prior to 131I to achieve more rapid symptom con-
trol. There is no real proof that pre-treatment with antithyroid drugs prevents exacerba-
tion of thyrotoxicosis after treatment, but the increase in TBII is less marked, and
exacerbations may thus be less severe.3 Resumption of antithyroid drugs after radioactive
iodine achieves symptom control but does not alter the outcome.4 Antithyroid drugs are
generally stopped 4–10 days before therapy and resumed 7 days after.
Genetics of Graves’ disease
Graves’ disease results from interaction between genetic and environmental factors. Up to
60% of patients have family history of autoimmune thyroid disease (AITD). About a
third of first-degree relatives will develop, or have developed, AITD, and around half will
be positive for autoantibodies. Concordance rates are higher for monozygotic twins than
for dizygotic twins. Genetic influences are thought to account for up 80% of the suscepti-
bility to Graves’ disease.5
The human leucocyte antigen (HLA) complex located at chromosome 6p21 has three
classes of antigen:
 class I—HLA-A, B and C
 class II—HLA DP, DQ and DR
 class III—complement, tumour necrosis factor (TNF)-, heat shock protein-70 and
other immune regulatory genes.
This is a highly polymorphic region of the genome, conferring susceptibility to a range
of diseases. HLA-DR3 is the most useful marker. Among patients with Graves’ disease
40–50% are HLA-DR3 positive, compared with 15–30% of the general population.
Recent studies have identified associations with other HLA alleles, most notably
DQA1*0501. HLA is probably important in all ethnic groups, but the precise associations
in non-Caucasians differ from the above. Cytotoxic T lymphocyte antigen-4 (CTLA-4),
located at chromosome 2q33, is a costimulatory molecule involved in interaction
between T lymphocytes and antigen-presenting cells. At least four polymorphisms have
been identified and confer susceptibility to autoimmune endocrine disease.6 Together,
HLA antigens and CTLA-4 confer around half the susceptibility to Graves’. Other candi-
date genes include immune regulatory genes, such as the vitamin D receptor, TSH recep-
tor and thyroglobulin.
Recent Developments
1 Wang et al.7 have shown that the A/G polymorphism at position 40 in exon 1 of
CTLA-4 may be a marker for relapse after antithyroid drug therapy. Early identifica-
tion of patients liable to relapse may allow us to target definitive treatment early.
2 The Nurses’ Health Study8 followed 115 109 women aged 25–42 over 12 years. The
incident diagnosis of Graves’ was 4.6 per 1000. Smoking was a risk factor (hazard ratio
PSEM-S1.qxd  10/4/06  8:46 AM  Page 3
§01 Thyroid4
Symptoms of
thyrotoxicosis
Isotope
scan*
Diagnostic doubt
Suspicious goitre
Graves’ diagnosed
Stabilize with ATD
Severe hyperthyroidism 
Large goitre 
High risk (e.g. cardiac failure)
Mild or moderate
hyperthyroidism
Definitive treatment:
131I (severe or high risk)
Surgery (large goitre) 
CBZ  20—60 mg/day
MMI  5—30 mg/day
PTU 100—300 mg/day
Monitor every 4-6 
weeks, decrease dose as
euthyroidism achieved
Monitor 3/12 for 1st year
then annually
Remission
Relapse
Definitive treatment
(Usually 131I)
2nd course ATD
Maintenance for (12/12),
e.g. CBZ 5 mg OD
FT3, FT3, and TSH  
Anti-TPO, Anti-Tg, TRAB
Fig. 1.1 Use of antithyroid drugs. *Scan with technetium-99m pertechnetate or iodide. ATD  antithyroid
drugs; CBZ  carbimazole; MMI methimazole; PTU  propylthiouracil; Tg  thyroglobulin; TPO  thyroid
peroxidase; TRAB TSH receptor antibodies.
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1.93). Obesity was associated with lower risk of Graves’—hazard ratio for individuals
with body mass index (BMI) greater than 30 kg/m2 was 0.68 (95% CI 0.49 to 0.92).
3 Colour Doppler sonography may be useful in diagnosis of thyroid disorders. This is
a safe, non-invasive technique to assess blood flow in the thyroid arteries. Results
correlate highly with thyroid volume and function. In a preliminary study,9 thyroid blood
flow at baseline was highly correlated with outcome after 14 months of antithyroid drug
therapy. Relapse could be predicted with a sensitivity of 71% and specificity of 100%.
Conclusions
Initial investigations should include thyroid hormone, TSH and thyroid antibodies,
including TBII. Full blood count and liver tests should be requested at baseline and at
intervals in patients taking antithyroid drugs (Figure 1.1). Thyroid scanning is not rou-
tinely warranted unless there is doubt about the diagnosis. Antithyroid drug treatment is
usually the first line treatment. Radioactive iodine has been increasingly used in recent
years. There is no evidence of teratogenicity. Obviously, it is absolutely contraindicated
during pregnancy and most endocrinologists would avoid its use within 6–12 months of
conception. The above patient should not be overly concerned about the implications of
the disease for her children although, if female, they will inherit a roughly one in three
lifetime chance of developing AITD.
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